BIO:ON Insight #7 · Jul 6, 2026
Fill the pipeline with AI, fend off generics, buy your way out: surviving the patent cliff
Takeda signs a $600M AI deal with Insilico, generic makers challenge Lilly's tirzepatide patents, and AbbVie buys Apogee for $10.9B. Three ways Big Pharma tries to survive the patent cliff.
What I learned this week
This week's three stories look different, but they read as one formula. As the patent cliff gets closer, Big Pharma reaches for AI, the courts, M&A, or all three at once. That matters beyond corporate strategy: the strategy a company picks decides which skills the market needs, and so the shape of the opportunities open to you. See you next issue. 🙏
Yaehyun Lee · Quoted from the Editor's Insight I wrote for this issue.
Stories in this issue
- Pipeline Analysis
Takeda × Insilico: $600M AI drug discovery partnership
TakedaInsilico Medicine
- Market Trends
Generic makers challenge Lilly's tirzepatide patents
Eli Lillytirzepatide
- Pipeline Analysis
AbbVie to acquire Apogee Therapeutics for $10.9B
AbbVieApogee Therapeutics
AI summary
- 1Takeda signed a $600M AI drug discovery deal with Insilico Medicine to help fill its patent cliff.
- 2Generic makers filed suits to invalidate Zepbound (tirzepatide) patents.
- 3AbbVie is acquiring Apogee Therapeutics for $10.9B, widening its atopic dermatitis and asthma franchise.
Relevant rolesBDInvestment & IRRegulatory affairs
Summary and tags generated by AI from the issue text.
References
- 1.
- 2.Generic drugmakers challenge Eli Lilly's tirzepatide patents (opens in a new tab)
Reuters / PharmaLive, Jun 29, 2026
- 3.AbbVie to acquire Apogee Therapeutics for $10.9B (opens in a new tab)
BioSpace, Jul 1, 2026
Related insights
Other issues covering the same companies, drugs or topics